Companies with a Future performance score of at least 3, ordered by Future performance score.
Starpharma Holdings Limited engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide.
Ecofibre Limited, together with its subsidiaries, engages in breeding, growing, processing, and distributing hemp products in the United States and Australia.
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders.
Botanix Pharmaceuticals Limited, a clinical stage cannabinoid therapeutics company, develops therapeutics for serious skin diseases in Australia.
AdAlta Limited, a drug discovery and development company, develops protein therapeutics.
Medical Developments International Limited manufactures and distributes pharmaceutical drugs, and medical and veterinary equipment.
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines.
Telix Pharmaceuticals Limited, an oncology company, develops molecularly targeted radiation products for unmet needs in cancer care in Australia.
Immutep Limited, a biotechnology company, engages in the research, development, and commercialization of biological products.
Opthea Limited, a biotechnology company, develops and commercializes therapies primarily for eye disease in Australia.
Genetic Signatures Limited operates as a molecular diagnostic (MDx) company in North America and Australia.
Probiotec Limited manufactures, markets, and distributes a range of prescription and over-the-counter pharmaceuticals, complementary medicines, and specialty ingredients in Australia and internationally.
Palla Pharma Limited, a vertically integrated pharmaceutical company, produces and distributes narcotic raw materials, active pharmaceutical ingredients, and finished dosage formulations for pharmaceutical markets in Australia and Norway.
Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, the United States, Korea, and internationally.
Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide.
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally.